Clinical trials can offer people with prostate cancer new treatment options, especially when standard treatments are no longer effective. Two studies underway are the MK-5684-01A trial by Merck and the EvoPAR-PR02 trial by AstraZeneca.
The MK-5684-01A trial is testing a new pill that lowers hormone levels to slow or stop prostate cancer growth. The EvoPAR-PR02 trial is another new study that targets cancer cells’ ability to repair themselves.
These studies are important steps toward developing new, more effective ways to treat prostate cancer. They also provide patients and their families with more treatment options and renewed hope for better outcomes.
“Clinical trials are part of your treatment options, and I encourage you to participate when applicable and available.”
-Keith Crawford, MD, PhD
What You Will Learn:
At the end of this session, attendees will be able to:
- Better understand prostate cancer clinical trials and their purpose
- Explain how clinical trials can be considered a part of treatment options
- Reviewing new clinical trials that may help stop or slow the spread of prostate cancer
Agenda
- Discuss Clinical Trials and Review the Find Your Trial (FYT) Tool: Dr. Crawford will provide an overview of clinical trials and review the Find Your Trial (FYT) tool.
- Clinical Trial Highlight: Dr. Crawford will review and answer questions about the Merck MK-5684 & AstraZeneca EvoPAR-PR02 clinical trials.
- Survivor Man-to-Man Session: An informal discussion among prostate cancer survivors attending the in-person meeting at Dana-Farber Cancer Institute.